Search

Your search keyword '"Lambaudie, E."' showing total 321 results
Start Over Author "Lambaudie, E." Publication Type Academic Journals
321 results on '"Lambaudie, E."'

3. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study

Author

Lenck, C., Chopin, N., Gouy, S., Bonsang-Kitzis, H., Martinez-Gomez, C., Radosevic-Robin, N., Martin, S., Lefeuvre-plesse, C., Lambaudie, E., Leblanc, E., Guyon, F., Classe, J.-M., Ramanah, R., Beurrier, F., Angeles, M.A., Pomel, C., Joly, F., de la Motte Rouge, T., Provansal, M., Lesoin, A., Floquet, A., Berton, D., Kalbacher, E., Chakiba, C., Meeus, P., Selle, F., Treilleux, I., Lecuru, F., Pautier, P., and Ray-Coquard, I.

Published
2020
Full Text
View/download PDF

5. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F, Gouy, S., Guyon, F., Lambaudie, E, Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A, Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

6. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F., Gouy, S., Guyon, F., Lambaudie, E., Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A., Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

7. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F., Gouy, S., Guyon, F., Lambaudie, E., Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A., Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

8. Positive or close margins: reoperation rate and second conservative resection or total mastectomy?

Author

Houvenaeghel G, Lambaudie E, Bannier M, Rua S, Barrou J, Heinemann M, Buttarelli M, Thomassin Piana J, and Cohen M

Subjects
breast cancer, conservative surgery, mastectomy, re-operation, margins., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Gilles Houvenaeghel,1 Eric Lambaudie,1 Marie Bannier,2 Sandrine Rua,2 Julien Barrou,2 Mellie Heinemann,1 Max Buttarelli,2 Jeanne Thomassin Piana,3 Monique Cohen2 1Department of Surgical Oncology, Paoli Calmettes Institute and CRCM, CNRS, INSERM, Aix Marseille Université, 13009 Marseille, France; 2Department of Surgical Oncology, Paoli Calmettes Institute, 13009 Marseille, France; 3Department of Pathology, Paoli Calmettes Institute and CRCM, CNRS, INSERM, 13009 Marseille, France Introduction: Reoperation after breast-conserving surgery (BCS) could be proposed for positive or close margins. Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient’s and tumor’s characteristics. We have analyzed our breast cancer (BC) database in order to determine second and third attempts for BCS and mastectomy rates, as well as associated factors for type of surgery. Methods: All patients with BCS between 1995 and 2017 were included. Patient’s characteristics, pathologic results, and treatments were analyzed. Reoperation rate, type of reoperation, second reoperation, and associated factors of reoperation, mastectomy, and third intervention were determined. Three periods were determined: P1–P3. Results: We analyzed 10,761 patients: 1,161 with ductal carcinoma in situ (DCIS) and 9,600 with invasive BC. The reoperation rate was 41.4% for DCIS and 28.0% for invasive BC. Using multivariate analysis, we identified tumor size >20 mm as being a risk factor for reoperation, whereas age >50 years, P2–3, and some localization decreased reoperation rates. For invasive BC, age >40 years, triple-negative tumors, neoadjuvant chemotherapy, and noncentral tumors decreased reoperation rates and lobular tumor, multifocal tumors, lymphovascular invasion, DCIS component, and Her2-positive tumors increased reoperation rates. For patients requiring reoperation, re-excision was performed in 48.1% (1,523/3,168) and mastectomy was required after first re-excision in 13.46% (205/1,523). For DCIS, mastectomy rates were higher for grade 2 and tumor ≥20 mm. For invasive BC, mastectomy rates were higher for lobular, multifocal, ≥20 mm, Her2-positive tumors and diffuse positive margins and lower for age >50 years and during the last period. Even if interval time between surgery and adjuvant treatments was higher for patients with reoperation, survival rates were not different between patients with and without reoperation. Conclusion: A decrease in reoperation and mastectomy rates had been reported with several associated factors. A third intervention with mastectomy was required in 13.5% of patients. This information should be done in case of reoperation. Keywords: breast cancer, conservative surgery, mastectomy, reoperation, margins

Published
2019

15. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study

Author

Martinez, A., Filleron, T., Rouanet, P., Méeus, P., Lambaudie, E., Classe, J. M., Foucher, F., Narducci, F., Gouy, S., Guyon, F., Marchal, F., Jouve, E., Colombo, P. E., Mourregot, A., Rivoire, M., Chopin, N., Houvenaeghel, G., Jaffre, I., Leveque, J., Lavoue, V., Leblanc, E., Morice, P., Stoeckle, E., Verheaghe, J. L., Querleu, D., and Ferron, G.

Published
2017
Full Text
View/download PDF

19. La chirurgie robotique en oncogynécologie

Author

Bougherara, L., Blache, G., Arsène, E., Jauffret, C., Azaïs, H., Laplane, C., Hudry, D., Atrous, G., Knight, S., Bresson, L., Kakkos, A., Narducci, F., Leblanc, E., Houvenaeghel, G., Bats, A.-S., Lécuru, F., Collinet, P., Marchal, F., and Lambaudie, E.

Published
2016
Full Text
View/download PDF

33. Erratum: Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

Author

Boudin, L, Gonçalves, A, Sabatier, R, Moretta, J, Sfumato, P, Asseeva, P, Livon, D, Bertucci, F, Extra, J-M, Tarpin, C, Houvenaeghel, G, Lambaudie, E, Tallet, A, Resbeut, M, Sobol, H, Charafe-Jauffret, E, Calmels, B, Lemarie, C, Boher, J-M, Viens, P, Eisinger, F, and Chabannon, C

Published
2017
Full Text
View/download PDF

49. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.

Author

Martinez, A., Filleron, T., Rouanet, P., Méeus, P., Lambaudie, E., Classe, J. M., Foucher, F., Narducci, F., Gouy, S., Guyon, F., Marchal, F., Jouve, E., Colombo, P. E., Mourregot, A., Rivoire, M., Chopin, N., Houvenaeghel, G., Jaffre, I., Leveque, J., and Lavoue, V.

Abstract

Background: Pelvic exenteration remains one of the most mutilating procedures, with important postoperative morbidity, an altered body image, and long-term physical and psychosocial concerns. This study aimed to assess quality of life (QOL) during the first year after pelvic exenteration for gynecologic malignancy performed with curative intent. Methods: A French multicentric prospective study was performed by including patients who underwent pelvic exenteration. Quality of life by measurement of functional and symptom scales was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (version 3.0) and the EORTC QLQ-OV28 questionnaires before surgery, at baseline, and 1, 3, 6, and 12 months after the procedure. Results: The study enrolled 97 patients. Quality of life including physical, personal, fatigue, and anorexia reported in the QLQ-C30 was significantly reduced 1 month postoperatively and improved at least to baseline level 1 year after the procedure. Body image also was significantly reduced 1 month postoperatively. Global health, emotional, dyspnea, and anorexia items were significantly improved 1 year after surgery compared with baseline values. Unlike younger patients, elderly patients did not regain physical and social activities after pelvic exenteration. Conclusions: Therapeutic decision on performing a pelvic exenteration can have a severe and permanent impact on all aspects of patients' QOL. Deterioration of QOL was most significant during the first 3 months after surgery. Elderly patients were the only group of patients with permanent decreased physical and social function. Preoperative evaluation and postoperative follow-up evaluation should include health-related QOL instruments, counseling by a multidisciplinary team to cover all aspects concerning stoma care, sexual function, and long-term concerns after surgery. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Survival after breast cancer local recurrence according to therapeutic strategies.

Author

Houvenaeghel, G., Boher, J.M., Michel, V., Bannier, M., Minsat, M., Tallet, A., Cohen, M., Buttarelli, M., Resbeut, M., and Lambaudie, E.

Subjects
BREAST cancer treatment, CANCER relapse, SURVIVAL analysis (Biometry), MASTECTOMY, INTERSTITIAL brachytherapy, LUMPECTOMY, CANCER treatment
Abstract

Aims To compare survival outcomes after mastectomy (Mt) and lumpectomy plus interstitial brachytherapy (LpIB) in the treatment of breast cancer local recurrence (LR) occurring after conservative surgery. Methods Medical records of patients treated for an isolated LR from January 1, 1981 to December 31, 2009 were reviewed. To overcome the bias due to the fact that treatment choice (Mt or LpIB) was based on prognostic factors with LpIB proposed preferentially to women with good prognosis, Mt and LpIB populations were matched and compared with regard to overall survival (OS) and metastasis free survival (MFS). Results Among 348 patients analyzed, 66.7% underwent Mt, 17.8% LpIB and 15.5% Lp alone. After a median follow-up of 73.3 months, 65 patients had died (42/232 Mt, 8/62 LpIB, 15/54 Lp). Before matching, OS and MFS at 5 years were significantly better in the LpIB compared to the Mt group, due to significantly more frequent poor prognostic factors in the latter (p = 0,07 and p = 0,09 respectively, log-rank significance limit of 10%). After matching, the benefits of LpIB disappeared since MFS and OS rates were not significantly different in both groups (p = 0.68 and 0.88 respectively). After LpIB, the second LR rate was 17% at 5 years and 30% at 10 years. Conclusion A second conservative breast cancer treatment associating lumpectomy and interstitial brachytherapy is possible for selected patients with LR, without decrease in neither OS nor MFS compared to mastectomy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results